Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer
Juan Zhou(Nanjing Medical University), Chunxia Su(Tongji University), Lihong Wu(Sun Yat-sen University), Ying Huang(Chengdu University), Xianxiu Ji(Tongji University), Lei Lei, Jing Zhao(University of Electronic Science and Technology of China), Yiran Cai(Burning Rock Biotech (China)), Guanghui Gao(Tongji University), Minwei Bao(Tongji University)
Cited by 21
Related Papers
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
|Lung Cancer|2013|178
Pan-cancer analysis of <i>ARID1A</i> Alterations as Biomarkers for Immunotherapy Outcomes
|Journal of Cancer|2019|142
Baicalein attenuates the quorum sensing-controlled virulence factors of Pseudomonas aeruginosa and relieves the inflammatory response in P.&nbsp;aeruginosa-infected macrophages by downregulating the MAPK and NF&kappa;B signal-transduction pathways
|Drug Design Development and Therapy|2016|121
Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
|Cancer Immunology Immunotherapy|2018|99